Related references
Note: Only part of the references are listed.AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
Paul R. Gavine et al.
CANCER RESEARCH (2012)
Increased Expression of Fibroblastic Growth Factor Receptor 2 Is Correlated With Poor Prognosis in Patients With Breast Cancer
Shanshan Sun et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
F. R. Lamont et al.
BRITISH JOURNAL OF CANCER (2011)
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma
Hikmat A. Al-Ahmadie et al.
JOURNAL OF PATHOLOGY (2011)
Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models
Matthew Squires et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Features and development of Coot
P. Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
A Structure-Guided Approach to Creating Covalent FGFR Inhibitors
Wenjun Zhou et al.
CHEMISTRY & BIOLOGY (2010)
Understanding resistance to EGFR inhibitors-impact on future treatment strategies
Deric L. Wheeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
N. Turner et al.
ONCOGENE (2010)
De-regulated FGF receptors as therapeutic targets in cancer
Victoria Knights et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Jalview Version 2-a multiple sequence alignment editor and analysis workbench
Andrew M. Waterhouse et al.
BIOINFORMATICS (2009)
Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Peter S. Hammerman et al.
CLINICAL CANCER RESEARCH (2009)
Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia
Dragana Milojkovic et al.
CLINICAL CANCER RESEARCH (2009)
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
Jing Qing et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
RUNX1T1 is overexpressed in imatinib mesylate-resistant cells
Renata Binato et al.
MOLECULAR MEDICINE REPORTS (2009)
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Nicola Normanno et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival
Kaiko Kunii et al.
CANCER RESEARCH (2008)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
Hung Huynh et al.
CLINICAL CANCER RESEARCH (2008)
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Mohammad Azam et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2008)
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer
D. C. Tomlinson et al.
JOURNAL OF PATHOLOGY (2007)
Knockdown by shRNA identifes S249C mutant FGFR3 as a potential therapeutic target in bladder cancer
D. C. Tomlinson et al.
ONCOGENE (2007)
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases:: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2007)
ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL
Katherine E. Ewings et al.
EMBO JOURNAL (2007)
Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease
Luigia Lombardi et al.
GENES CHROMOSOMES & CANCER (2007)
Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma
Jonathan J. Keats et al.
LEUKEMIA & LYMPHOMA (2006)
Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations
HS Radomska et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Anticipating clinical resistance to target-directed agents - The BCR-ABL paradigm
Mohammad Azam et al.
MOLECULAR DIAGNOSIS & THERAPY (2006)
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
AH Jebar et al.
ONCOGENE (2005)
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
S Trudel et al.
BLOOD (2005)
Cellular signaling by fibroblast growth factor receptors
VP Eswarakumar et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest
DE Todd et al.
ONCOGENE (2004)
Strategies to overcome resistance to targeted protein kinase inhibitors
H Daub et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines
ME Ray et al.
CANCER RESEARCH (2004)
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma
S Trudel et al.
BLOOD (2004)
Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim
R Ley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease
DM Ornitz et al.
GENES & DEVELOPMENT (2002)
Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway -: Correlation with resistance to etoposide-induced apoptosis
OE Pardo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes
Jo Vandesompele et al.
GENOME BIOLOGY (2002)
Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations
D Ronchetti et al.
ONCOGENE (2001)
Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors
C Billerey et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
AML1-ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia
T Pabst et al.
NATURE MEDICINE (2001)
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma
M Chesi et al.
BLOOD (2001)
Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE
SL Tannheimer et al.
BREAST CANCER RESEARCH (2000)
Share Paper
